BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 33664179)

  • 1. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
    Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
    Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
    Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
    Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
    Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
    Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
    Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
    Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
    Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation Cyclophosphamide.
    Chorão P; Henriques M; Villalba M; Montoro J; Balaguer-Roselló A; González EM; Gómez MD; Gómez I; Solves P; Santiago M; Asensi P; Lamas B; Bataller A; Granados P; Eiris J; Martínez D; Louro A; Rebollar P; Perla A; Salavert M; de la Rubia J; Sanz MÁ; Sanz J
    Transplant Cell Ther; 2024 May; 30(5):538.e1-538.e10. PubMed ID: 38331195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation - A Single Centre Study.
    Studer U; Khanna N; Leuzinger K; Hirsch HH; Heim D; Lengerke C; Tsakiris DA; Halter J; Gerull S; Passweg J; Medinger M; Gwerder M
    Anticancer Res; 2020 Oct; 40(10):5909-5917. PubMed ID: 32988922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation.
    Mizuno K; Sakurai M; Kato J; Yamaguchi K; Abe R; Koda Y; Kataoka K; Mori T
    Transpl Infect Dis; 2022 Dec; 24(6):e13904. PubMed ID: 35870130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
    Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
    Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
    Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
    Jung S; Michel M; Stamminger T; Michel D
    BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
    Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
    Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients.
    Kachur E; Roshdy D; Hamadeh I; Dodd B; Shahid Z
    Transpl Infect Dis; 2021 Apr; 23(2):e13502. PubMed ID: 33171005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
    Koch K; Osswald L; Miller I; Braitsch K; Götze K; Bassermann F; Herhaus P; Verbeek M
    Anticancer Res; 2022 Nov; 42(11):5431-5441. PubMed ID: 36288861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
    Derigs P; Radujkovic A; Schubert ML; Schnitzler P; Schöning T; Müller-Tidow C; Hegenbart U; Schönland SO; Luft T; Dreger P; Schmitt M
    Ann Hematol; 2021 Aug; 100(8):2087-2093. PubMed ID: 33270162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
    Chen TT; David AP; Barthelmess EK; MacBrayne CE
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
    Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
    Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
    Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.